The new strategy of NK cell therapy with death receptors for the patients with chollangiocellular carcinoma or mixed liver cancer

探讨自然杀伤（NK）细胞治疗高度恶性型胆管细胞癌（CCC）和混合型肝癌的新策略。根据我们的临床CCC标本，超过90%的患者DR-4表达升高。另一方面，我们可以发现MUC5是影响CCC患者生存的独立预后因素之一。我们也证实了人NK细胞对人CCC细胞系HuCCT1的杀伤作用呈剂量依赖性。这些事实将提示NK细胞联合死亡受体和抗体依赖性免疫应答治疗CCC患者的可能性。

We investigated the new strategy of natural killer (NK) cell therapy for patients with cholangiocellular carcinoma (CCC) and mixed liver cancer that were highly malignant type of liver cancer. According to our clinical specimens of CCC, more than 90% of patients elevated DR-4 expression. On the other hand, we could detect that MUC5 was one of the independent prognostic factors in survival of CCC patients. We have also confirmed human NK cells killed HuCCT1 which was cell line of human CCC, in dose dependent manner. The facts would indicated the possibility of NK cell therapy with death receptor and Ab-dependent immune response for CCC patients.